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Abstract
Background: Success in further reducing the burden of cardiovascular disease (CVD) is threatened by the increasing
prevalence of obesity-related atherogenic dyslipidemia. HDL-cholesterol (HDL-C) level is inversely correlated with CVD risk;
each 1 mg/dl decrease in HDL-C is associated with a 6% reduction in risk. We previously showed that a common CNR1
haplotype, H3 (frequency 20%), is protective against the reduction in HDL-C that typically accompanies weight gain. In the
present study, we extend that observation by reporting the effect of CNR1 haplotype on HDL-C response to modification of
dietary fat intake in weight maintenance and weight loss.
Methods: Six haplotype tagging SNPs that cover the CNR1 gene locus were genotyped in 590 adults of varying body mass
index (cohort 1 is 411 males with BMI 18.5–30.0 kg/m
2; cohort 2 is 71 females with BMI18.5–30.0 kg/m
2; and cohort 3 is 108
females with BMI 30–39.9 kg/m
2). Dietary intakes were modified so that fat intake in the ‘‘high fat’’ condition was 15–20%
greater than in the ‘‘low fat’’ condition, and lipid profiles were compared between carriers versus noncarriers for each of the
five commonly observed CNR1 haplotypes (H1–H5).
Results: In normal to overweight subjects on eucaloric diets, the H3 haplotype was significantly associated with short-term
high fat diet induced changes in HDL-C level in females (carriers 5.9 mg/dl.noncarriers, p=0.007). The H3 haplotype was
also significantly associated with HDL-C level after 16 weeks on high fat calorie restricted diet in obese females (carriers
6.8 mg/dl.noncarriers, p=0.009).
Conclusion: Variability within the CNR1 gene locus contributes to gender-related differences in the HDL-cholesterol
response to change in dietary fat intake. Functional characterization of this relationship in vitro may offer insights that
potentially yield therapeutic guidance targeting dietary macronutrient composition, a direction much needed in the current
epidemic of obesity.
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Introduction
Obesity is associated with an atherogenic lipoprotein profile
characterized by increased very low-density lipoprotein triglycer-
ides (VLDL-TG), small dense low density lipoprotein cholesterol
(LDL-C), and decreased circulating high density lipoprotein
cholesterol (HDL-C) [1]. The anti-inflammatory properties of
HDL-C and its role in reverse cholesterol transport make it a
significant modulator of risk for the development of cardiovascular
disease (CVD). As event rate is inversely correlated with HDL-C
concentration, each 1 mg/dl decrease in HDL-C is associated
with a 6% reduction in CVD risk [2]. Decreased HDL-C is
especially important in the current epidemic of obesity as higher
body mass index (BMI) is associated with lower HDL-C levels in
all racial/ethnic groups [3]. Notably, the prevalence of subthresh-
old (‘‘at risk’’) HDL-C levels has improved three-fold more in men
than women (Q5.6% versus Q1.8%) over the past 30 years [4]. In
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36166fact, the strongest clinically-relevant demographic predictors of
plasma HDL-C concentration are BMI and gender [5,6].
While modest weight loss of 5–10% improves plasma lipopro-
tein profile [7] and modifying dietary macronutrient intake can
increase HDL-C level [8], scientific and clinical debate continues
regarding the importance of the relative amount of fat in a
calorically restricted diet [9,10]. Low-fat (LF) diets can increase
circulating VLDL-TG levels, reduce HDL-C, and thus, adversely
affect atherogenic dyslipidemia [11,12]. Although meta-analyses
show greater improvements in HDL-C on high fat (HF) diets
[13,14], some studies yield conflicting results [15,16]. Overall, the
lipoprotein response to dietary macronutrient composition is a
highly variable and complex trait [11], influenced by BMI [17],
gender [18], and individual genetic characteristics [19,20].
Preclinical and clinical studies targeting the endocannabinoid
system (ECS) reveal potent effects on body weight, body fat
distribution, and lipoprotein metabolism. The ECS consists
primarily of two phospholipid-derived signaling molecules, N-
arachidonoylethanolamide (anandamide) and 2-arachidonoylgly-
cerol (2-AG), and two G protein-coupled receptors, CB1 and CB2
[21]. Most of the metabolic effects of ECS signaling appear to be
mediated through CB1 receptors in central and peripheral tissues.
In randomized clinical trials, CB1 receptor blockade resulted in
weight loss, with increased HDL-C levels that exceeded the
magnitude of change expected from weight loss alone [22,23].
Collectively, these observations suggest that the ECS regulates
lipid homeostasis via peripheral mechanisms that are at least
partially independent of weight change.
Consistent with this hypothesis, we previously reported that
sequence variation in CB1 (gene name CNR1) is associated with
variability in circulating HDL-C levels independent of BMI
[24,25]. Importantly, a common CNR1 haplotype, H3, was further
protective against the marked reduction in HDL-C that occurs in
severe obesity (BMI$40 kg/m
2) [25]. However, it remains
unknown whether the CNR1 H3 haplotype influences the effect
of dietary fat intake on lipoprotein profiles. We tested this question
in adults across a range of BMI who were prescribed various
percentages of dietary fat intakes. Herein, we provide evidence
that the response of HDL-C to increased dietary fat intake during
weight maintenance is strongly influenced by the CNR1 H3
haplotype in women. We also report that this same H3 haplotype
may protect women against low circulating HDL-C during
voluntary weight loss.
Methods
Three distinct cohorts comprising 590 adults who participated
in clinical trials designed to modify the percentage of dietary fat
consumed were studied. Cohort #1 (normal to overweight males)
and cohort #2 (normal to overweight females) were convenience
samples from prior trials using eucaloric diets designed for weight
maintenance. Because we had previously found an association
between CNR1 and HDL-C in a population sample that was
predominantly female [26,27], we enrolled more males (cohort
#1) than females (cohort #2) in the present study (at a ratio of 4:1)
to assure that we would not be missing a significant relationship in
males. As the strength of the genotype-phenotype associations in
cohorts #1&#2 were consistent with our prior work, cohort #3
consisted of a sample of obese females on a calorically restricted
diet, which not only broadened our range of BMI in females to
better match current population demographics, but also allowed
investigation of the effects of dietary fat intake within the context
of weight loss.
For all subjects, the amount of fat prescribed in the ‘‘high fat’’
(HF) conditions were 15% higher than in the ‘‘low fat’’ (LF)
conditions. Dietary intakes were assessed by Registered Dietitians
(RDs) from 4-day food diaries and 24-hour diet recalls using multi-
pass methodology [28]. Energy and macronutrient intake analysis
was performed using Nutrition Data System for Research (NDS,
Nutrition Coordinating Center, University of Minnesota, Minne-
apolis). Written informed consent was obtained and study
protocols were approved by the Institutional Review Boards of
Children’s Hospital and Research Center of Oakland and the
E.O. Lawrence Berkeley National Laboratory at the University of
California for cohorts #1&#2 and the Vanderbilt University
Medical Center for cohort #3.
Cohort #1: Males on Eucaloric Diet
Males age 21–60 years with BMI 18.9–30 kg/m
2 who had
participated in one of four trials [26,29,30,31,32] were included if
they had no active chronic disease, did not take lipid altering
medications, and were nonsmokers. Males were randomly
assigned in a crossover design to eucaloric HF diet (prescribed
as 35% fat [,18% saturated, 11% monounsaturated, 6%
polyunsaturated], 50% carbohydrate, 15% protein) and LF diet
(prescribed as 20% fat [,5% saturated, 11% monounsaturated,
4% polyunsaturated], 65% carbohydrate [half simple and half
complex], 15% protein) for 6 weeks each. Cholesterol content of
the prescribed diets was 125 mg/1000 kcal and fiber content was
5 g/1000 kcal. Subjects maintained habitual physical activity and
weighed themselves daily. RDs adjusted menu energy content
when necessary to maintain weight. Diet compliance was assessed
from 4-day weighed food intake records and daily recording of
menu items consumed. Height, weight and venous blood samples
were collected at baseline and end of study in an overnight fasted
state. Plasma total cholesterol and triglyceride levels were
determined by enzymatic procedures on a Gilford Impact 400E
or Express 550 Plus analyzer (Ciba Corning, Oberlin, OH). HDL-
C was measured after dextran sulfate precipitation of plasma and
LDL-C was calculated from the Friedewald formula [33].
Cohort #2: Females on Eucaloric Diet
Premenopausal females age 21–50 years with BMI 18.9–30 kg/
m
2 were included if they had no active chronic disease, did not
take lipid altering medications, were nonsmokers, and were not
pregnant, breastfeeding or taking oral contraceptives [27].
Although not randomly crossed over, females were prescribed
similar eucaloric HF and LF diets as the males in cohort #1
(above) for 8 week periods. The same procedures as described for
cohort #1 were followed for compliance and outcome measure-
ments.
Cohort #3: Females on Calorie Restricted Diet
Premenopausal females age 21–50 years with BMI 30–39.9 kg/
m
2 were included if they had no active chronic disease, did not
take medications for lipid metabolism, were nonsmokers, and were
not pregnant, breastfeeding or taking oral contraceptives. After
habituation on the lower fat diet condition (35% fat), subjects were
prescribed a 15% calorically restricted HF diet (50% fat [1/3
saturated, 1/3 monounsaturated, 1/3 polyunsaturated], 30%
carbohydrate [half simple and half complex], 20% protein) for
16 weeks. Cholesterol content of the HF diet was 150 mg/
1000 kcal and fiber content was 7 g/1000 kcal. Standard assays
were performed for triglyceride, total cholesterol, LDL-C and
HDL-C by selective enzymatic hydrolysis at the Vanderbilt
Department of Pathology Clinical Laboratory. Serum glucose
was quantified by colorimetric timed endpoint method and serum
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model assessment of insulin resistance (HOMA-IR) was calculated
as [fasting glucose (mM) x fasting insulin (mU/L)]/22.5 [34].
Genotyping
Genomic DNA was extracted from whole blood according to
standard procedures. Based on our prior work [24,25], we tagged
the entire CNR1 gene plus 5 kilobases (kb) upstream and 5 kb
downstream using Haploview (http://www.broad.mit.edu/mpg/
haploview/) for linkage disequilibrium analysis [35] and selection
of tagSNPs. Gene locus, haplotype structure and allele frequencies
of the tagSNPs covering the variability within our locus of interest
(Chromosome 6, physical position 88, 901, 306–88, 916, 775) are
shown in Figure 1. These six tagSNPs include two promoter SNPs
(rs806370, rs806369), one coding SNP (rs1049353), two SNPs in
the 39 untranslated region (39-UTR: rs12720071, rs806368), and
one SNP distal to the polyA tail (rs806366). The tagSNPs were
genotyped for cohorts #1&#2 using multiplex polymerase chain-
reaction (PCR), single base primer extension (SBE), and
generation of mass spectra (Sequenom, San Diego, CA). For
cohort #3, genotyping was conducted using commercial Taqman
Allelic discrimination assays (Applied Biosystems, Inc., Foster City,
CA) [36]. Each assay contained two Taqman probes uniquely
labeled to bind separate (major versus minor) alleles.
Statistical Analysis
Statistical analyses were conducted using SPSS version 17
(SPSS Inc., Chicago, IL), JMP version 7.0 (SAS Institute Inc.,
Cary, NC) and PLINK genetic analyses toolset version 1.07
(http://pngu.mgh.harvard.edu/,purcell/plink) [37]. Data are
expressed as means and standard deviations unless otherwise
noted. Baseline lipid variables among cohorts were assessed using
the Kruskal-Wallis test and relationships between demographics
and lipids were examined using Spearman Rho correlations.
Minor allele frequency and Hardy-Weinberg (H-W) equilibrium
statistics were calculated for each SNP. As we have previously
demonstrated that haplotypes provide greater power than single
SNPs for identifying associations related to CNR1 [25], we
performed haplotype analyses based on a dominant model (carrier
versus noncarrier). Five CNR1 haplotypes (Figure 1) were identified
at frequency over 5%. From 59 to 39, they are CCAATT (23%),
CTGATC (30%), CCGATC (20%), TCGACT (13%), CCGGCT
(7%). These five are the most common CNR1 haplotypes found in
the Centre d’Etude du Polymorphisme Humain (CEPH) cohort
within the International HapMap Consortium and in our prior
cohorts [24]. Although the tagging SNPs were, by definition, in
tight linkage dysequilibrium, we corrected for multiple hypothesis
testing of the five haplotypes [38] and considered results
statistically significant only with p value,0.01.
For cohorts #1 and #2, the five CNR1 haplotypes were
estimated using PHASE software. As expected, the same five
haplotypes were observed in cohort #3. However, the greater
racial diversity of this cohort introduced more structural variability
at the CNR1 gene locus, and thus, we identified two novel CNR1
haplotypes (CCGGTT, frequency 0.7%; and CCGATT, frequen-
cy 2%) in the African American (AA) females (data not presented).
Importantly, these two new haplotypes were not significantly
associated with HDL-C levels. For cohort #3, haplotypes were
estimated by applying standard E-M algorithms located in the –
hap option of PLINK.
All genotype-phenotype association analyses were performed
using the five CNR1 haplotypes. In cohorts #1 and #2, linear
regression models were created to examine relationships between
haplotypes and lipid variables. Data were adjusted for age and
baseline BMI. To be consistent with this approach, for cohort #3
a linear regression model was applied to test each haplotype (versus
all other haplotypes) using the –hap-linear option in PLINK. For
cohort #3, which was obese by definition, baseline BMI and
HOMA-IR were significantly associated with baseline serum
HDL-C, and thus, included as covariates in the model using the –
covar option. This approach allowed us to replicate our initial
findings from cohorts #1& #2 in a second independent cohort
(cohort #3) to reduce the likelihood of a spurious association
between CNR1 and HDL-C levels.
Results
Subject Characteristics
The combined sample included 411 males and 179 females with
a mean age of 39.964.0 years (Table 1). As defined by eligibility
criteria, subjects in cohorts #1&#2 were normal to overweight
(mean BMI 24.861.7 kg/m
2), while cohort #3 subjects were
obese (mean BMI 34.762.7 kg/m
2). Ninety percent of subjects in
cohorts #1&#2 self-identified as being of European ancestry
(EA). In cohort #3, 75 (69%) females self-identified as EA and 33
Figure 1. The CNR1 gene: chromosomal location, tagSNPs, haplotype structure and alleles. *The CNR1 gene locus covers ,15 kb on
Chromosome 6 (chromosome 6 is shown in the reverse orientation, with arm q on the left). Six haplotype tagging SNPs were genotyped, based upon
our prior work [25], and reference sequence numbers for the tag SNPs are presented. These SNPs are inherited in combination (haplotypes).
doi:10.1371/journal.pone.0036166.g001
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were similar across cohorts. There were no significant associations
between minor allele frequency and diet adherence (data not
presented).
Cohort #1
As expected with eucaloric diets, no significant changes
occurred in body weight in cohort #1 subjects. In these normal
to overweight males, HF diet significantly decreased TG
(230.2663.6 mg/dl, p,0.001), increased total cholesterol
(+12.0621.9 mg/dl, p,0.001), increased LDL-C
(+11.5620.6 mg/dl, p,0.001) and increased HDL-C
(+6.465.7 mg/dl, p,0.001). Consistent with previous report in a
predominantly female cohort [24], the reduction in TG was
significantly greater in male noncarriers of the CNR1 H4
haplotype compared to male carriers (at least one copy),
p=0.005. Although prior work also indicated that the CNR1 H3
haplotype was associated with HDL-C in both genders, in the
present study H3 was not significantly associated with HDL-C
response to high fat diet in normal to overweight males (Table 2);
male carriers of the H3 haplotype had only a 1.3 mg/dl higher
Table 1. Baseline characteristics of study subjects (n=590).
Characteristics Cohort #1 Cohort #2 Cohort #3
Sample Size 411 71 108
Male/Female Male Female Female
Age, mean (SD), y 45.0 (11.5) 38.2 (6.5) 37.5 (0.7)
BMI*, mean (SD) 25.4 (3.0) 23.2 (3.1) 36.7 (1.1)
Total cholesterol,
mean (SD), mg/dL
197.9 (35.1) 186.3 (31.0) 168.1 (29.3)
Triglycerides, mean (SD), mg/dL 129.6 (77.4) 80.7 (44.2) 85.1 (48.2)
HDL-C, mean (SD), mg/dL 46.6 (12.2) 60.3 (11.3) 48.9 (12.8)
LDL-C, mean (SD), mg/dL 125.7 (30.4) 109.8 (29.1) 102.1 (25.0)
Abbreviations: SD, standard deviation; BMI, body mass index; HDL-C, high
density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
*Calculated as weight in kilograms divided by height in meters squared.
doi:10.1371/journal.pone.0036166.t001
Table 2. Effect of haplotype on triglycerides, LDL-cholesterol and HDL-cholesterol in 411 normal to overweight males (Cohort #1)
on eucaloric diets.
Triglyceride, mg/dl (SD) LDL Cholesterol, mg/dl (SD) HDL Cholesterol, mg/dl (SD)
Haplotype Non-Carrier Carrier P-Value
Non-
Carrier Carrier P-Value
Non-
Carrier Carrier P-Value
H1
Sample Size 241 170 241 170 241 170
LF 137.4 (100.2) 145.5 (91.4) 0.81 118.0 (32.7) 109.6 (30.8) 0.007 40.9 (9.0) 39.2 (9.7) 0.29
HF 112.3 (99.7) 108.2 (72.9) 0.19 129.3 (35.1) 121.4 (34.8) 0.02 47.2 (10.9) 45.7 (12.3) 0.65
Difference 225.1 (61.7) 237.4 (65.7) 0.09 11.3 (19.5) 11.8 (22.2) 0.72 6.3 (5.5) 6.5 (6.0) 0.45
H2
Sample Size 191 220 191 220 191 220
LF 146.3 (107.3) 135.9 (86.3) 0.67 112.7 (32.4) 116.1 (32.0) 0.19 39.7 (9.2) 40.6 (9.4) 0.51
HF 121.0 (117.2) 101.6 (54.0) 0.21 122.7 (34.1) 128.9 (35.8) 0.04 46.0 (11.8) 47.1 (11.2) 0.50
Difference 225.3 (67.9) 234.3 (59.4) 0.20 10.0 (21.1) 12.8 (20.2) 0.10 6.3 (5.8) 6.5 (5.6) 0.77
H3
Sample Size 284 127 284 127 284 127
LF 143.6 (95.6) 134.5 (99.0) 0.14 113.8 (31.1) 116.2 (34.5) 0.60 40.1 (9.4) 40.5 (9.2) 0.77
HF 111.6 (94.6) 108.3 (77.5) 0.42 126.4 (34.3) 125.2 (37.1) 0.56 46 (11.5) 47.8 (11.4) 0.16
Difference 231.9 (65.0) 226.2 (60.4) 0.58 12.6 (20.5) 9.0 (20.7) 0.05 6.0 (5.7) 7.3 (5.6) 0.03
H4
Sample Size 303 108 303 108 303 108
LF 139.9 (91.4) 143.2 (110.4) 0.97 114.4 (32.8) 115.0 (30.3) 0.65 39.8 (9.4) 41.2 (9.3) 0.20
HF 104.6 (62.2) 127.4 (139.9) 0.11 126.9 (35.8) 123.7 (33.2) 0.13 46.4 (11.2) 47.0 (12.2) 0.76
Difference 235.3 (60.4) 215.8 (70.2) 0.005 12.5 (21.0) 8.7 (19.5) 0.06 6.6 (5.6) 5.8 (6.0) 0.17
H5
Sample Size 328 63 328 63 328 63
LF 142.0 (98.2) 133.7 (88.2) 0.60 113.7 (31.7) 119.2 (34.2) 0.22 40.2 (9.5) 40.2 (8.6) 0.56
HF 112.7 (94.1) 98.8 (57.7) 0.49 124.9 (35.1) 132.3 (35.2) 0.14 46.7 (11.6) 46.0 (10.8) 0.27
Difference 229.3 (65.7) 234.9 (50.4) 0.44 11.2 (20.4) 13.1 (21.9) 0.56 6.5 (5.7) 5.7 (5.4) 0.23
Abbreviations: LF, low fat diet; HF, high fat diet.
P-values are presented after adjusting for age and baseline BMI; statistical significance level established at a=0.01.
doi:10.1371/journal.pone.0036166.t002
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noncarriers (from 40.169.4 to 46.0611.5 mg/dl).
Cohort #2
Like the males in cohort #1, females in cohort #2 experienced
no significant changes in body weight. In this cohort, HF diet
significantly decreased TG (217.5634.1 mg/dl, p,0.001), in-
creased total cholesterol (+12.2619.8 mg/dl, p,0.001), increased
LDL-C (+4.8617.0 mg/dl, p=0.02) and increased HDL-C
(+10.968.7 mg/dl, p,0.001). In contrast to the males in cohort
#1, the CNR1 H3 haplotype was strongly associated (p=0.007)
with high fat diet induced changes in serum HDL-C levels in these
normal to overweight females (Table 3). The increase in HDL-C
level after HF diet in normal to overweight female carriers of the
H3 haplotype (from 4968 to 62.8611.2 mg/dl) was 5.9 mg/dl
greater than the increase in noncarriers (from 49.8610.9 to
57.7610.9 mg/dl) (Figure 2a).
Cohort #3
The obese females experienced a significant weight loss of
6.263.5 kg over the 16-week intervention (p,0.001) due to the
15% caloric restriction prescribed in the HF diet condition.
Overall, cohort #3 experienced significantly decreased BMI
(22.561.5 units, p,0.001), total cholesterol (29.6619.2 mg/dl,
p,0.001), LDL-C (28.0617.6 mg/dl, p,0.001), plasma insulin
(22.0364.79 mg/dl, p=0.001), and had non-significant changes
in TG (25.58633.6 mg/dl, p=0.178), HDL-C (0.3067.90 mg/
dl, p=0.758), and plasma glucose (21.16610.3 mg/dl, p=0.360).
As with normal to overweight females, the CNR1 H3 haplotype
was strongly associated with serum HDL-C levels in obese females,
p=0.009 (Table 4). After 16 weeks of high fat diet, obese female
carriers of the H3 haplotype had significantly higher HDL-C levels
(52.362.3 mg/dl) than noncarriers (45.561.4 mg/dl) (Figure 2b).
In re-testing the EA obese females alone, the H3 haplotype
remained significantly associated (p=0.005) with HDL-C level,
and thus, the relationship was independent of race. The
relationship between H3 haplotype and HDL-C was also
independent of circulating TG level (p=0.06 for the association
between H3 haplotype and TG/HDL-C ratio).
Discussion
The present findings demonstrate that variability in the CNR1
gene influences HDL-C response to changes in dietary fat intake.
In normal to overweight adults on eucaloric diets, subjects
Table 3. Effect of haplotype on triglycerides, LDL-cholesterol and HDL-cholesterol in 71 normal to overweight females (cohort #2)
on eucaloric diet.
Triglyceride, mg/dl (SD) LDL Cholesterol, mg/dl (SD) HDL Cholesterol, mg/dl (SD)
Haplotype Non-Carrier Carrier P-Value Non-Carrier Carrier P-Value Non-Carrier Carrier P-Value
H1
Sample Size 42 29 42 29 42 29
LF 93.5 (47.5) 105.0 (47.4) 0.18 104.5 (25.5) 105.8 (39.7) 0.91 48.3 (9.8) 50.9 (8.8) 0.26
HF 74.1 (37.1) 90.2 (52.0) 0.08 110.5 (28.3) 108.7 (30.6) 0.82 60.5 (11.5) 59.9 (11.2) 0.74
Difference 219.4 (32.7) 214.8 (36.3) 0.53 6.1 (15.7) 2.9 (18.8) 0.56 12.2 (8.1) 9.0 (9.2) 0.14
H2
Sample Size 42 29 42 29 42 29
LF 100.9 (54.1) 94.3 (36.4) 0.75 104 (34.5) 106.5 (28.0) 0.71 49.5 (8.6) 49.2 (10.8) 0.89
HF 86.5 (51.9) 72.3 (28.4) 0.31 108.7 (28.5) 111.4 (30.4) 0.68 59.8 (10.1) 61 (12.9) 0.68
Difference 214.4 (35.5) 222.0 (32.0) 0.37 4.7 (15.0) 4.9 (19.8) 0.97 10.3 (7.7) 11.7 (10.0) 0.52
H3
Sample Size 35 36 35 36 35 36
LF 107.3 (54.9) 89.4 (37.7) 0.61 108.1 (37.7) 102 (25.0) 0.93 49.8 (10.9) 49.0 (8.0) 0.13
HF 88.9 (53.2) 72.7 (32.0) 0.95 108.9 (32.4) 110.6 (25.9) 0.42 57.7 (10.9) 62.8 (11.2) 0.33
Difference 218.4 (32.1) 216.7 (36.3) 0.60 0.8 (19.2) 8.6 (13.8) 0.11 7.9 (6.2) 13.8 (9.7) 0.007
H4
Sample Size 51 20 51 20 51 20
LF 91.0 (35.2) 116.5 (67.5) 0.81 101.5 (26.7) 113.9 (41.7) 0.55 50.1 (9.3) 47.6 (9.8) 0.78
HF 71.2 (27.5) 104.9 (65.9) 0.58 106.8 (26.1) 117.4 (35.2) 0.44 62 (11.6) 55.8 (9.4) 0.37
Difference 219.8 (33.2) 211.7 (36.3) 0.57 5.3 (15.2) 3.5 (21.3) 0.77 12 (9.7) 8.2 (4.3) 0.20
H5
Sample Size 68 3 68 3 68 3
LF 97.6 (47.3) 112.7 (60.9) 0.33 105.3 (31.2) 98 (52.4) 0.97 49.4 (9.5) 48.3 (10.1) 0.54
HF 81.1 (45.0) 71.7 (14.4) 0.61 110.2 (29.0) 101.7 (37.1) 0.78 60.4 (11.4) 57.7 (9.0) 0.36
Difference 216.5 (33.5) 241.0 (47.1) 0.25 4.8 (17.2) 3.7 (15.5) 0.58 11.0 (8.9) 9.3 (1.2) 0.68
Abbreviations: LF, low fat diet; HF, high fat diet.
P-values are presented after adjusting for age and baseline BMI; statistical significance level established at a=0.01.
doi:10.1371/journal.pone.0036166.t003
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HDL-C level during high fat intake and the magnitude of the
effect of the H3 haplotype on HDL-C was four-fold greater in
females compared to males. We observed a similar response to
high fat intake in females with class I and II obesity who were
prescribed caloric restriction. After 16 weeks of high fat diet, obese
female carriers of the H3 haplotype had HDL-C levels that were
,7 mg/dl greater than noncarriers (52.362.3 mg/dl in carriers
versus 45.561.4 mg/dl in noncarriers, p=0.009). The current
findings are consistent with prior evidence that the CNR1 H3
haplotype was strongly associated with HDL-C levels in individ-
uals with class III obesity [25].
It is important to recognize that the frequency of the H3
haplotype does not differ by gender and is common (20%
frequency) in the general population. Given that women
disproportionately seek dietary approaches for weight loss [39],
along with the increasing recognition that women are at significant
risk for cardiovascular disease - particularly in the current
obesogenic environment, it is imperative to understand factors
that determine favorable lipoprotein responses to dietary weight
loss interventions. Prior investigation indicates that women may be
more sensitive to diet induced changes in HDL-C during weight
loss than men [40]. For example, a recent comparison of popular
weight loss diets showed women had markedly increased HDL-C
on 50% dietary fat intake (Atkins diet: ,5 mg/dl increase in
HDL-C), moderately increased HDL-C on 30% fat intake (Zone
and Learn diets: ,2.5 mg/dl increase in HDL-C) and no change
in HDL-C on 10% fat intake (Ornish diet) [41]. The gender
distinction observed in HDL-C response to popular weight loss
diets may in part be attributable to underlying variability in the
CNR1 gene.
The specific physiological mechanism linking the CNR1 gene
product to lipid homeostasis is not completely understood. The
CB1 receptor modulates food intake through an effect on central
neuronal circuits [42]. Central CB1 receptor signaling is also
known to directly influence peripheral metabolic processes
involved in VLDL-TG secretion and clearance [43,44]. Although
changes in the abundance of VLDL could alter circulating HDL-
C levels, by shifting the flux of free fatty acids between larger and
smaller lipoproteins [45], our data do not support such a
conclusion. In the present study, it appears that CNR1 modulated
HDL-C response to high fat diet independent of BMI and fasting
TG level. Peripherally, the CB1 receptor is expressed in the liver
[46], pancreas, gastrointestinal tract [47] and adipose tissue [48].
HDL particle composition, and therefore HDL clearance rate, is
modified within these tissues through the action of lipolytic
enzymes [49]. Studies conducted using conditional (hepatic) CB1
knockout mice have shown that the CB1 receptor directly regulates
hepatic lipid metabolism [50]. Lipoprotein lipase (LPL) and
hepatic lipase (HL) convert larger HDL particles into smaller HDL
remnants, resulting in HDL particles that are cleared more rapidly
from the circulation. Endothelial lipase (EL) is also a strong
predictor of circulating HDL-C concentration [51,52], and EL
expression is modulated by adipocytokines [53]. Because CB1
antagonists modulate the synthesis and secretion of adiponectin
[54] and pro-inflammatory cytokines like TNFa [55,56], genetic
variability in CNR1 may be affecting HDL-C level through a
mechanism involving its intravascular modeling. While our study
was limited to assessment of HDL-C concentration, future
investigation is needed to address more mechanistic hypotheses
regarding the distribution of particle subfraction and changes in
inflammatory biomarkers within the HDL proteome. In addition,
large datasets are needed to condition the genetic effect of CNR1
on LPL, HL and EL, as well as known functional variants in the
ATP-binding cassette transporter A1 (ABCA1), cholesteryl ester
transfer protein (CETP), and scavenger receptor class B type 1
(SRB1). While all are known to influence HDL-C level [5,51,57],
combinatorial models assessing interactions [58] will require
targeted genotyping within cohorts of enormous size.
As these studies proceed, it is important to recognize that the
causative allele linking CNR1 to HDL-C level remains undeter-
mined. It is likely that the H3 haplotype examined in the present
study is only in partial linkage (ie, D9,1.0) with the actual
functional allele, a group of common and rare variants with the
capacity to alter CNR1 gene function [59,60]. To fully characterize
these variants, future investigation must target deep re-sequencing
of the CNR1 gene in individuals expressing H3, from cohorts of
racially diverse populations enriched for the traits of interest. In
Figure 2. Effect of H3 haplotype on serum HDL-cholesterol levels in women. Values shown are mean+standard error. In normal to
overweight females, changing from low fat (LF) to high fat (HF) diet increased HDL-C from 49.068.0 mg/dl to 62.8611.2 mg/dl in H3 haplotype
carriers and from 49.8610.9 mg/dl to 57.7610.9 mg/dl in H3 non-carriers. In obese females, calorically restricted (215% kcal) HF diet increased HDL-
C from 50.11611.60 mg/dl to 52.29610.38 mg/dl in H3 haplotype carriers and decreased HDL-C from 47.99612.90 mg/dl to 45.4968.95 mg/dl in H3
non-carriers.
doi:10.1371/journal.pone.0036166.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36166conclusion, we have demonstrated that the common H3 haplotype
at the CNR1 gene locus potently influences HDL-C response to
change in dietary fat intake in a gender-specific manner.
Functional characterization of this relationship may further our
understanding of the biology underlying lipid homeostasis, and
potentially yield therapeutic guidance to improve public health by
optimizing dietary macronutrient modifications, a direction much
needed in the current epidemic of obesity.
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